

By: Representatives Willis, Paden, Reynolds

To: Drug Policy

HOUSE BILL NO. 1547
(As Sent to Governor)

1 AN ACT TO AMEND SECTION 41-29-113, MISSISSIPPI CODE OF 1972,
2 TO REVISE SCHEDULE I OF THE CONTROLLED SUBSTANCES ACT TO INCLUDE
3 CERTAIN SYNTHETIC CANNABINOIDS, FENTANYLS AND FENTANYL-LIKE
4 SUBSTANCES THAT HAVE NO ACCEPTED MEDICAL USE; TO AMEND SECTION
5 41-29-115, MISSISSIPPI CODE OF 1972, TO AMEND SCHEDULE II TO
6 EXCLUDE NALDEMEDINE; TO AMEND SECTION 41-29-121, MISSISSIPPI CODE
7 OF 1972, TO REVISE SCHEDULE V TO INCLUDE A CANNABINOID THAT HAS
8 BEEN APPROVED AS A LEGEND DRUG BY THE FEDERAL FOOD AND DRUG
9 ADMINISTRATION; TO CREATE A TASK FORCE TO STUDY THE CULTIVATION OF
10 HEMP AND MAKE RECOMMENDATIONS; AND FOR RELATED PURPOSES.

11 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI:

12 **SECTION 1.** Section 41-29-113, Mississippi Code of 1972, is
13 amended as follows:

14 41-29-113. * * *

15 **SCHEDULE I**

16 (a) Schedule I consists of the drugs and other substances,
17 by whatever official name, common or usual name, chemical name, or
18 brand name designated, that is listed in this section.

19 (* * *b) **Opiates.** Unless specifically excepted or unless
20 listed in another schedule, any of the following opiates,
21 including their isomers, esters, ethers, salts and salts of
22 isomers, esters and ethers, * * * whenever the existence of these



23 isomers, esters, ethers and salts is possible within the specific
24 chemical designation:

25 (1) Acetyl-alpha-methylfentanyl;

26 (2) Acetyl Fentanyl

27 N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide;

28 (3) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)
29 cyclohexylmethyl]benzamide);

30 (4) Acetylmethadol;

31 (5) Allylprodine;

32 (6) Alphacetylmethadol, except levo-alphacetylmethadol
33 (levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM);

34 (7) Alphameprodine;

35 (8) Alphamethadol;

36 (9) Alpha-methylfentanyl;

37 (10) Alpha-methylthiofentanyl;

38 (11) Benzethidine;

39 (12) Betacetylmethadol;

40 (13) Beta-hydroxyfentanyl;

41 (14) Beta-hydroxy-3-methylfentanyl;

42 (15) Betameprodine;

43 (16) Betamethadol;

44 (17) Betaprodine;

45 (18) Butyrl fentanyl

46 (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide);

47 (19) Clonitazene;



48 (* * *20) Dextromoramide;

49 (* * *21) Diampromide;

50 (* * *22) Diethylthiambutene;

51 (* * *23) Difenoquin;

52 (* * *24) Dimenoxadol;

53 (* * *25) Dimepheptanol;

54 (* * *26) Dimethylthiambutene;

55 (* * *27) Dioxaphetyl butyrate;

56 (* * *28) Dipipanone;

57 (* * *29) Ethylmethylthiambutene;

58 (* * *30) Etonitazene;

59 (* * *31) Etoxadine;

60 (* * *32) Fentanyl-related substances, meaning any

61 substance not otherwise listed under another schedule and for

62 which no exemption or approval is in effect under Section 505 of

63 the Federal Food, Drug, and Cosmetic Act [21 USC 355] that is

64 structurally related to fentanyl by one or more of the following

65 modifications:

66 (A) Replacement of the phenyl portion of the

67 phenethyl group by any monocycle, whether or not further

68 substituted in or on the monocycle;

69 (B) Substitution in or on the phenethyl group with

70 alkyl, alkenyl, alkoxy, hydroxy, halo, haloalkyl, amino or nitro

71 groups;



72 (C) Substitution in or on the piperidine ring with
73 alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, halo, haloalkyl,
74 amino or nitro groups;

75 (D) Replacement of the aniline ring with any
76 aromatic monocycle whether or not further substituted in or on the
77 aromatic monocycle; and/or

78 (E) Replacement of the N-propionyl group by
79 another acyl group.

80 Fentanyl-related substances include, but are not limited to,
81 cyclopropyl fentanyl,

82 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide);

83 Furanyl-Fentanyl,

84 (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-2-carboxamide);

85 valeryl fentanyl,

86 (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide);

87 para-fluorobutyryl fentanyl,

88 (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);

89 para-methoxybutyryl fentanyl,

90 (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide);

91 para-chloroisobutyryl fentanyl,

92 (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);

93 isobutyryl fentanyl,

94 (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide);



95 cyclopentyl fentanyl,
96 (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide);
97 and
98 ocfentanil,
99 (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetami
100 de);

- 101 (* * *33) Furethidine;
102 (* * *34) Hydroxypethidine;
103 (* * *35) Ketobemidone (including the optical and
104 geometric isomers);
105 (* * *36) Levomoramide;
106 (* * *37) Levophenacylmorphane;
107 (* * *38) 3-methylfentanyl;
108 (* * *39) 3-methylthiofentanyl;
109 (* * *40) Morpheridine;
110 (* * *41) MPPP

111 (1-methyl-4-phenyl-4-propionoxypiperidine);

112 * * *

113 (42)

114 *N*-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-*N*-phenylprop
115 ionamide, its isomers, esters, ethers, salts and salts of isomers,
116 esters and ethers (other names: beta-hydroxythiofentanyl);

117 (43) Noracymethadol;

118 (44) Norlevorphanol;

119 (45) Normethadone;



- 120 (46) Norpipanone;
- 121 (47) Para-fluorofentanyl;
- 122 (48) PEPAP
- 123 (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- 124 (49) Phenadoxone;
- 125 (50) Phenampromide;
- 126 (51) Phenomorphan;
- 127 (52) Phenoperidine;
- 128 (53) Piritramide;
- 129 (54) Proheptazine;
- 130 (55) Properidine;
- 131 (56) Propiram;
- 132 (57) Racemoramide;
- 133 (58) Thiofentanyl;
- 134 (59) Tilidine;
- 135 (60) Trimeperidine;
- 136 (61) U-47700,

137 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide.

138 (* * *c) **Opium derivatives.** Unless specifically excepted
139 or unless listed in another schedule, any of the following opium
140 derivatives, their salts, isomers and salts of isomers, * * *
141 whenever the existence of these salts, isomers and salts of
142 isomers is possible within the specific chemical designation:

- 143 (1) Acetorphine;
- 144 (2) Acetyldihydrocodeine;



- 145 (3) Benzylmorphine;
146 (4) Codeine methylbromide;
147 (5) Codeine-N-Oxide;
148 (6) Cyprenorphine;
149 (7) Desomorphine;
150 (8) Dihydromorphine;
151 (9) Drotebanol;
152 (10) Etorphine (except hydrochloride salt);
153 (11) Heroin;
154 (12) Hydromorphinol;
155 (13) Methyldesorphine;
156 (14) Methyldihydromorphine;
157 (15) Monoacetylmorphine;
158 (16) Morphine methylbromide;
159 (17) Morphine methylsulfonate;
160 (18) Morphine-N-Oxide;
161 (19) Myrophine;
162 (20) Nicocodeine;
163 (21) Nicomorphine;
164 (22) Normorphine;
165 (23) Pholcodine;
166 (24) Thebacon.
- 167 (* * *d) **Hallucinogenic substances.** Unless specifically
168 excepted or unless listed in another schedule, any material,
169 compound, mixture or preparation which contains any quantity of



170 the following substances, their salts, isomers (whether optical,
171 positional, or geometric) and salts of isomers, * * * whenever the
172 existence of these salts, isomers and salts of isomers is possible
173 within the specific chemical designation:

- 174 (1) Alpha-ethyltryptamine;
- 175 (2) 4-bromo-2,5-dimethoxy-amphetamine;
- 176 (3) 4-bromo-2,5-dimethoxyphenethylamine;
- 177 (4) 2,5-dimethoxyamphetamine;
- 178 (5) 2,5-dimethoxy-4-ethylamphetamine (DOET);
- 179 (6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine
180 (2C-T-7);
- 181 (7) 4-methoxyamphetamine;
- 182 (8) 5-methoxy-3,4-methylenedioxy-amphetamine;
- 183 (9) 4-methyl-2,5-dimethoxy-amphetamine;
- 184 (10) 3,4-methylenedioxy amphetamine;
- 185 (11) 3,4-methylenedioxymethamphetamine (MDMA);
- 186 (12) 3,4-methylenedioxy-N-ethylamphetamine (also known
187 as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl
188 MDA, MDE, MDEA);
- 189 (13) N-hydroxy-3,4-methylenedioxyamphetamine (also
190 known as N-hydroxy MDA, N-OHMDA, and
191 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine);
- 192 (14) 3,4,5-trimethoxy amphetamine;
- 193 (15) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT);
- 194 (16) Alpha-methyltryptamine (also known as AMT);



- 195 (17) Bufotenine;
- 196 (18) Diethyltryptamine;
- 197 (19) Dimethyltryptamine;
- 198 (20) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT);
- 199 (21) Ibogaine;
- 200 (22) Lysergic acid diethylamide (LSD);
- 201 (23) (A) Marijuana (Cannabidiol contained in a legend
202 drug product approved by the Federal Food and Drug Administration
203 or obtained under Section 41-29-136 is exempt under Schedule I);
- 204 (B) Hashish;
- 205 (24) Mescaline;
- 206 (25) Parahexyl;
- 207 (26) Peyote;
- 208 (27) N-ethyl-3-piperidyl benzilate;
- 209 (28) N-methyl-3-piperidyl benzilate;
- 210 (29) Psilocybin;
- 211 (30) Psilocyn;
- 212 (31) Tetrahydrocannabinols, meaning
213 tetrahydrocannabinols contained in a plant of the genus Cannabis
214 (cannabis plant), as well as the synthetic equivalents of the
215 substances contained in the cannabis plant, or in the resinous
216 extractives of such plant, and/or synthetic substances,
217 derivatives, and their isomers with similar chemical structure and
218 pharmacological activity to those substances contained in the
219 plant such as the following:



- 220 (A) 1 cis or trans tetrahydrocannabinol;
221 (B) 6 cis or trans tetrahydrocannabinol;
222 (C) 3,4 cis or trans tetrahydrocannabinol.

223 (Since nomenclature of these substances is not
224 internationally standardized, compounds of these structures,
225 regardless of atomic positions, are covered.)

226 ("Tetrahydrocannabinols" excludes dronabinol and nabilone.)

227 However, the following products are exempted from control:

228 (i) THC-containing industrial products made
229 from cannabis stalks (e.g., paper, rope and clothing);

230 (ii) Processed cannabis plant materials used
231 for industrial purposes, such as fiber retted from cannabis stalks
232 for use in manufacturing textiles or rope;

233 (iii) Animal feed mixtures that contain
234 sterilized cannabis seeds and other ingredients (not derived from
235 the cannabis plant) in a formula designed, marketed and
236 distributed for nonhuman consumption;

237 (iv) Personal care products that contain oil
238 from sterilized cannabis seeds, such as shampoos, soaps, and body
239 lotions (if the products do not cause THC to enter the human
240 body); and

241 (v) Processed cannabis plant extract, oil or
242 resin with a minimum ratio of twenty-to-one cannabidiol to
243 tetrahydrocannabinol (20:1 cannabidiol:tetrahydrocannabinol), and
244 diluted so as to contain at least fifty (50) milligrams of



245 cannabidiol per milliliter, with not more than two and one-half
246 (2.5) milligrams of tetrahydrocannabinol per milliliter;
247 (32) Phencyclidine;
248 (33) Ethylamine analog of phencyclidine (PCE);
249 (34) Pyrrolidine analog of phencyclidine (PHP, PCPy);
250 (35) Thiophene analog of phencyclidine;
251 (36) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine (TCPy);
252 (37) 4-methylmethcathinone (mephedrone);
253 (38) 3,4-methylenedioxypropylvalerone (MDPV);
254 (39) 2-(2,5-dimethoxy-4-ethylphenyl)ethanamine (2C-E);
255 (40) 2-(2,5-dimethoxy-4-methylphenyl)ethanamine (2C-D);
256 (41) 2-(4-chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
257 (42) 2-(4-iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
258 or 2,5-dimethoxy-4-iodophenethylamine;
259 (43) 2-[4-(ethylthio)-2,5-dimethoxyphenyl]ethanamine
260 (2C-T-2);
261 (44)
262 2-[4-(isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4);
263 (45) 2-(2,5-dimethoxyphenyl)ethanamine (2C-H);
264 (46) 2-(2,5-dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
265 (47) 2-(2,5-dimethoxy-4-(n)-propylphenyl)ethanamine
266 (2C-P);
267 (48) 3,4-methylenedioxy-N-methylcathinone (methylone);



268 (49)
269 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
270 (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36);
271 (50)
272 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine
273 (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82);
274 (51)
275 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine or
276 N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I;
277 Cimbi-5);
278 (52) 7-bromo-5-(2-chlorophenyl)-1,3-dihydro-2H-1,
279 4-benzodiazepin-2-one (also known as Phenazepam);
280 (53) 7-(2-chlorophenyl)-4-ethyl-13-methyl-3-thia-1,8,
281 11,12-tetraazatricyclo[8.3.0.0]trideca-2(6),4,7,10,12-pentaene
282 (also known as Etizolam);
283 (54) Salvia divinorum;
284 (55) Synthetic cannabinoids. Unless specifically
285 excepted or unless listed in another schedule, any material,
286 compound, mixture, or preparation which contains any quantity of a
287 synthetic cannabinoid found in any of the following chemical
288 groups, whether or not substituted to any extent, or any of those
289 groups which contain any synthetic cannabinoid salts, isomers, or
290 salts of isomers, whenever the existence of such salts, isomers,
291 or salts of isomers is possible within the specific chemical



292 designation, including all synthetic cannabinoid chemical
293 analogues in such groups:

294 (A) (6aR,10aR)-9-(hydroxymethyl)-6,
295 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]
296 chromen-1-ol (also known as HU-210 or
297 1,1-dimethylheptyl-11-hydroxy-delta8-tetrahydrocannabinol);

298 (B) Naphthoylindoles and naphthylmethylindoles,
299 being any compound structurally derived from 3-(1-naphthoyl)indole
300 or 1H-indol-3-yl-(1-naphthyl)methane, whether or not substituted
301 in the indole ring to any extent, or in the naphthyl ring to any
302 extent;

303 (C) Naphthoylpyrroles, being any compound
304 structurally derived from 3-(1-naphthoyl)pyrrole, whether or not
305 substituted in the pyrrole ring to any extent, or in the naphthyl
306 ring to any extent;

307 (D) Naphthylmethylindenes, being any compound
308 structurally derived from 1-(1-naphthylmethyl)indene, whether or
309 not substituted in the indene ring to any extent or in the
310 naphthyl ring to any extent;

311 (E) Phenylacetylindoles, being any compound
312 structurally derived from 3-phenylacetylindole, whether or not
313 substituted in the indole ring to any extent or in the phenyl ring
314 to any extent;

315 (F) Cyclohexylphenols, being any compound
316 structurally derived from 2-(3-hydroxycyclohexyl)phenol, whether



317 or not substituted in the cyclohexyl ring to any extent or in the
318 phenolic ring to any extent;

319 (G) Benzoylindoles, whether or not substituted in
320 the indole ring to any extent or in the phenyl ring to any extent;

321 (H) Adamantoylindoles, whether or not substituted
322 in the indole ring to any extent or in the adamantoyl ring system
323 to any extent;

324 (I) Tetrahydro derivatives of cannabinal and
325 3-alkyl homologues of cannabinal or of its tetrahydro derivatives,
326 except where contained in cannabis or cannabis resin;

327 (J) 3-Cyclopropylmethanone indole or
328 3-Cyclobutylmethanone indole or 3-Cyclopentylmethanone indole by
329 substitution at the nitrogen atom of the indole ring, whether or
330 not further substituted in the indole ring to any extent, whether
331 or not substituted on the cyclopropyl, cyclobutyl or cyclopentyl
332 rings to any extent;

333 (K) Quinoliny ester indoles, being any compound
334 structurally derived from 1H-indole-3carboxylic acid-8-quinoliny
335 ester, whether or not substituted in the indole ring to any extent
336 or the quinolone ring to any extent;

337 (L) 3-carboxamide-1H-indazoles, whether or not
338 substituted in the indazole ring to any extent and substituted to
339 any degree on the carboxamide nitrogen and
340 3-carboxamide-1H-indoles, whether or not substituted in the indole



341 ring to any extent and substituted to any degree on the
342 carboxamide nitrogen;

343 (M) Cycloalkanemethanone Indoles, whether or not
344 substituted at the nitrogen atom on the indole ring, whether or
345 not further substituted in the indole ring to any extent, whether
346 or not substituted on the cycloalkane ring to any extent.

347 (* * *e) **Depressants.** Unless specifically excepted or
348 unless listed in another schedule, any material, compound,
349 mixture, or preparation which contains any quantity of the
350 following substances having a depressant effect on the central
351 nervous system, including their salts, isomers, and salts of
352 isomers, whenever the existence of such salts, isomers, and salts
353 of isomers is possible within the specific chemical designation:

354 (1) Gamma-hydroxybutyric acid (other names include:
355 GHB, gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic
356 acid; sodium oxybate; sodium oxybutyrate);

357 (2) Mecloqualone;

358 (3) Methaqualone.

359 (* * *f) **Stimulants.** Any material, compound, mixture or
360 preparation which contains any quantity of the following central
361 nervous system stimulants including optical salts, isomers and
362 salts of isomers unless specifically excepted or unless listed in
363 another schedule:

364 (1) Aminorex;



365 (2) N-benzylpiperazine (also known as BZP * * * and
366 1-benzylpiperazine);

367 (3) Cathinone;

368 (4) Fenethylamine;

369 (5) Methcathinone;

370 (6) 4-methylaminorex (also known as
371 2-amino-4-methyl-5-phenyl-2-oxazoline);

372 (7) N-ethylamphetamine;

373 (8) Any material, compound, mixture or preparation
374 which contains any quantity of N,N-dimethylamphetamine. (Other
375 names include: N,N,-alpha-trimethyl-benzeneethanamine * * * and
376 N,N-alpha-trimethylphenethylamine);

377 (9) **Synthetic cathinones.** (A) Unless listed in
378 another schedule, any compound other than bupropion that is
379 structurally derived from 2-Amino-1-phenyl-1-propanone by
380 modification in any of the following ways:

381 (i) By substitution in the phenyl ring to any
382 extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide
383 substituents, whether or not further substituted in the phenyl
384 ring by one or more other univalent substituents;

385 (ii) By substitution at the 3-position with
386 an alkyl substituent;

387 (iii) By substitution at the nitrogen atom
388 with alkyl or dialkyl groups, or by inclusion of the nitrogen atom
389 in a cyclic structure.



390 (B) The compounds covered in this paragraph (9)
391 include, but are not limited to, any material compound, mixture or
392 preparation which contains any quantity of a synthetic cathinone
393 found in any of the following compounds, whether or not
394 substituted to any extent, or any of these compounds which contain
395 any synthetic cathinone, or salts, isomers, or salts of isomers,
396 whenever the existence of such salts, isomers or salts of isomers
397 is possible, unless specifically excepted or listed in another
398 schedule:

- 399 (i) 4-methyl-N-ethylcathinone ("4-MEC");
400 (ii) 4-methyl-alpha-pyrrolidinopropiophenone
401 ("4-MePPP");
402 (iii) Alpha-pyrrolidinopentiophenone
403 (" α -PVP");
404 (iv)
405 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one ("butylone");
406 (v) 2-(methylamino)-1-phenylpentan-1-one
407 ("pentedrone");
408 (vi)
409 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one
410 ("pentylone");
411 (vii) 4-fluoro-N-methylcathinone ("4-FMC");
412 (viii) 3-fluoro-N-methylcathinone ("3-FMC");



413 (ix)
414 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one
415 ("naphyrone"); * * *
416 (x) Alpha-pyrrolidinobutiophenone
417 (" α -PBP") * * * ; and
418 (xi)
419 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one
420 (N-ethylpentylone, ephylone).

421 **SECTION 2.** Section 41-29-115, Mississippi Code of 1972, is
422 amended as follows:

423 41-29-115. (* * *a) The controlled substances listed in
424 this section, by whatever official name, common or usual name,
425 chemical name, or brand name designated, are included in Schedule
426 II.

427 **SCHEDULE II**

428 (* * *b) **Substances, vegetable origin or chemical**
429 **synthesis.** Unless specifically excepted or unless listed in other
430 schedules, any of the following substances, * * * whether produced
431 directly or indirectly by extraction from substances of vegetable
432 origin, or independently by means of chemical synthesis, or by
433 combination of extraction and chemical synthesis:

434 (1) Opium and opiate, and any salt, compound,
435 derivative, or preparation of opium or opiate, excluding
436 apomorphine, thebaine-derived butorphanol, dextrorphan,



437 nalbuphine, naldemedine, nalmeffene, naloxegol, naloxone and
438 naltrexone, but including the following:

- 439 (i) Codeine;
- 440 (ii) Dihydroetorphine;
- 441 (iii) Ethylmorphine;
- 442 (iv) Etorphine hydrochloride;
- 443 (v) Granulated opium;
- 444 (vi) Hydrocodone, whether alone or in combination
445 with any material, compound, mixture or preparation;
- 446 (vii) Hydromorphone;
- 447 (viii) Metopon;
- 448 (ix) Morphine;
- 449 (x) Opium extracts;
- 450 (xi) Opium fluid extracts;
- 451 (xii) Oripavine;
- 452 (xiii) Oxycodone;
- 453 (xiv) Oxymorphone;
- 454 (xv) Powdered opium;
- 455 (xvi) Raw opium;
- 456 (xvii) Thebaine;
- 457 (xviii) Tincture of opium * * *;

458 (2) Any salt, compound, isomer, derivative, or
459 preparation thereof which is chemically equivalent or identical
460 with any of the substances referred to in paragraph (1), but not
461 including the isoquinoline alkaloids of opium;



462 (3) Opium poppy and poppy straw;
463 (4) Coca leaves and any salt, compound, derivative, or
464 preparation of cocaine or coca leaves, including cocaine and
465 ecgonine and any salt, compound, derivative, isomer, or
466 preparation thereof which is chemically equivalent or identical
467 with any of these substances, but not including:

468 (i) Decocainized coca leaves or extraction of coca
469 leaves, which extractions do not contain cocaine or ecgonine; or

470 (ii) Ioflupane;

471 (5) Concentrate of poppy straw (the crude extract of
472 poppy straw in either liquid, solid or powder form which contains
473 the phenanthrene alkaloids of the opium poppy).

474 (* * *c) **Opiates.** Any of the following opiates, including
475 their isomers, esters, ethers, salts, and salts of isomers,
476 whenever the existence of these isomers, esters, ethers and salts
477 is possible within the specified chemical designation, dextrorphan
478 and levopropoxyphene excepted:

479 (1) Alfentanil;

480 (2) Alphaprodine;

481 (3) Anileridine;

482 (4) Bezitramide;

483 (5) Bulk dextropropoxyphene (nondosage forms);

484 (6) Carfentanil;

485 (7) Dihydrocodeine;

486 (8) Diphenoxylate;



487 (9) Fentanyl;
488 (10) Isomethadone;
489 (11) Levo-alpha-acetylmethadol
490 (levo-alpha-acetylmethadol, levomethadyl acetate, LAAM);
491 (12) Levomethorphan;
492 (13) Levorphanol;
493 (14) Metazocine;
494 (15) Methadone;
495 (16) Methadone-intermediate,
496 4-cyano-2-dimethylamino-4,4-diphenyl butane;
497 (17) Moramide-intermediate,
498 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid;
499 (18) Pethidine (meperidine);
500 (19) Pethidine-Intermediate-A,
501 4-cyano-1-methyl-4-phenylpiperidine;
502 (20) Pethidine-Intermediate-B,
503 ethyl-4-phenylpiperidine-4-carboxylate;
504 (21) Pethidine-Intermediate-C,
505 1-methyl-4-phenylpiperidine-4-carboxylic acid;
506 (22) Phenazocine;
507 (23) Piminodine;
508 (24) Racemethorphan;
509 (25) Racemorphan;
510 (26) Remifentanil;
511 (27) Sufentanil;



512 (28) Tapentadol;
513 (29) Thiafentanil,
514 4-(methoxycarbonyl)-4-(N-phenmethoxyacetamido)-1-[2-(thienyl)ethyl
515]piperidine.

516 (* * *d) **Stimulants.** Any material, compound, mixture, or
517 preparation which contains any quantity of the following
518 substances:

519 (1) Amphetamine, its salts, optical isomers, and salts
520 of its optical isomers;

521 (2) Phenmetrazine and its salts;

522 (3) Any substance which contains any quantity of
523 methamphetamine, including its salts, isomers, and salts of
524 isomers;

525 (4) Methylphenidate and its salts;

526 (5) Lisdexamfetamine, its salts, isomers and salts of
527 isomers.

528 (* * *e) **Depressants.** Unless specifically exempted or
529 unless listed in another schedule, any material, compound,
530 mixture, or preparation which contains any quantity of the
531 following substances:

532 (1) Amobarbital;

533 (2) Secobarbital;

534 (3) Pentobarbital;

535 (4) Glutethimide.

536 (* * *f) **Hallucinogenic substances.**



537 (1) Dronabinol oral solution
538 [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)];
539 (2) Nabilone [other names include:
540 (+/-)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-
541 hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo(b,d)pyran-9-one].

542 (* * *g) **Immediate precursors.** Unless specifically
543 excepted or unless listed in another schedule, any material,
544 compound, mixture, or preparation which contains any quantity of
545 the following substances:

546 (1) Amphetamine and methamphetamine immediate
547 precursor: Phenylacetone (other names include:
548 phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl
549 ketone);

550 (2) Phencyclidine immediate precursors:
551 (i) 1-phenylcyclohexylamine;
552 (ii) 1-piperidinocyclohexanecarbonitrile (PCC);

553 (3) Fentanyl immediate precursor:
554 4-anilino-N-phenethyl-4-piperidine (ANPP).

555 (* * *h) Any material, compound, mixture or preparation
556 which contains any quantity of a Schedule II controlled substance
557 and is listed as an exempt substance in 21 CFR, Section 1308.24 or
558 1308.32, shall be exempted from the provisions of the Uniform
559 Controlled Substances Law.

560 **SECTION 3.** Section 41-29-121, Mississippi Code of 1972, is
561 amended as follows:



562 41-29-121. * * *

563 **SCHEDULE V**

564 (a) Schedule V consists of the drugs and other substances,
565 by whatever official name, common or usual name, chemical name, or
566 brand name designated, listed in this section.

567 (b) Narcotic drugs. [Reserved]

568 (* * *c) **Narcotic drugs containing nonnarcotic active**
569 **medicinal ingredients.** Any compound, mixture or preparation
570 containing * * * any of the following narcotic drugs, or their
571 salts calculated as the free anhydrous base or alkaloid, in
572 limited quantities as set forth below, which also contains one or
573 more nonnarcotic active medicinal ingredients in sufficient
574 proportion to confer upon the compound, mixture or
575 preparation * * * valuable * * * medicinal qualities other than
576 those possessed by the narcotic drug alone:

577 (1) Not more than two hundred (200) milligrams of
578 codeine, or any of its salts, per one hundred (100) milliliters or
579 per one hundred (100) grams;

580 (2) Not more than one hundred (100) milligrams of
581 dihydrocodeine, or any of its salts, per one hundred (100)
582 milliliters or per one hundred (100) grams;

583 (3) Not more than one hundred (100) milligrams of
584 ethylmorphine, or any of its salts, per one hundred (100)
585 milliliters or per one hundred (100) grams;



586 (4) Not more than two and five-tenths (2.5) milligrams
587 of diphenoxylate and not less than twenty-five (25) micrograms of
588 atropine sulphate per dosage unit;

589 (5) Not more than one hundred (100) milligrams of opium
590 per one hundred (100) milliliters or per one hundred (100) grams;

591 (6) Not more than five-tenths (0.5) milligram of
592 difenoxin and not less than twenty-five (25) micrograms of
593 atropine sulfate per dosage unit.

594 (* * *d) **Stimulants.** Unless specifically excepted or
595 listed in another schedule, any material, compound, mixture or
596 preparation which contains any quantity of the following
597 substance, including its salts, isomers and salts of isomers:
598 Pyrovalerone.

599 (* * *e) **Depressants.** Unless specifically exempted or
600 excluded or unless listed in another schedule, any material,
601 compound, mixture or preparation which contains any quantity of
602 the following substances having a depressant effect on the central
603 nervous system, including their salts, isomers and salts of
604 isomers:

605 (1) Brivaracetam
606 ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also
607 referred to as BRV; UCB-34714; Briviact);

608 (2) Ezogabine [N-[2-amino-4-(4-
609 fluorobenzylamino)-phenyl]-carbamic acid ethyl ester];



610 (3) Lacosamide
611 [(R)-2-acetoamido-N-benzyl-3-methoxy-propionamide];

612 (4) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic
613 acid].

614 (f) Approved cannabidiol drugs. A drug product in finished
615 dosage formulation that has been approved by the United States
616 Food and Drug Administration that contains cannabidiol
617 (2-R-3-methyl-6R-1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-
618 benzenediol) derived from cannabis and no more than 0.1 percent
619 (w/w) residual tetrahydrocannabinols.

620 (* * *g) Any material, compound, mixture or preparation
621 which contains any quantity of a Schedule V controlled substance
622 and is listed as an exempt substance in 21 CFR, Section 1308.22,
623 1308.24, 1308.26, 1308.32 or 1308.34, shall be exempted from the
624 provisions of the Uniform Controlled Substances Law.

625 **SECTION 4.** (1) There is created the Mississippi Hemp
626 Cultivation Task Force which shall be composed of thirteen (13)
627 members as follows:

628 (a) The Commissioner of Agriculture and Commerce or a
629 designee;

630 (b) The President of Mississippi State University or a
631 designee;

632 (c) The President of Alcorn State University or a
633 designee;



634 (d) A director of the University of Mississippi School
635 of Pharmacy National Center for Natural Products Research or a
636 designee;

637 (e) The President of the Delta Council or a designee;

638 (f) A representative of the Mississippi Secretary of
639 State's office;

640 (g) A representative of the Mississippi Attorney
641 General's office;

642 (h) The Director of Pharmacy, Mississippi State
643 Department of Health or a designee;

644 (i) A member of the Mississippi House of
645 Representatives designated by the Speaker of the House;

646 (j) A member of the Mississippi Senate designated by
647 the Lieutenant Governor;

648 (k) The Commissioner of Public Safety or a designee;

649 (l) The President of the Mississippi Farm Bureau
650 Federation or a designee; and

651 (m) A designee of the Governor.

652 (2) The Commissioner of Agriculture and Commerce, or the
653 Commissioner's designee, shall chair the task force and shall call
654 the first meeting, at which the task force shall elect a vice
655 chair from its membership and shall adopt rules for transacting
656 its business and keeping records. Members of the task force shall
657 receive a per diem in the amount provided in Section 25-3-69 for
658 each day engaged in the business of the task force. Members of



659 the task force other than the legislative members shall receive
660 reimbursement for travel expenses incurred while engaged in
661 official business of the task force in accordance with Section
662 25-3-41 and the legislative members of the task force shall
663 receive the expense allowance provided in Section 5-1-47.

664 (3) The duties of the task force shall be to:

665 (a) Make a comprehensive study of the potential for
666 cultivation of hemp in this state. Reports shall be provided to
667 the Legislature each year at least one (1) month before the
668 convening of the regular session.

669 (b) Examine and study approaches taken by other states
670 in the monitoring and regulation of hemp cultivation.

671 (c) Study the economic costs and benefits of hemp
672 cultivation, market potential, and potential job creation.

673 (4) The Mississippi Department of Agriculture and Commerce
674 shall supply the necessary staff and research assistance to the
675 Task Force in its work.

676 (5) This section shall stand repealed on July 1, 2020.

677 **SECTION 5.** This act shall take effect and be in force from
678 and after July 1, 2019.

